Phase III Results Position Selecta/Sobi’s SEL-212 As Tough Competition For Krystexxa In Gout
Executive Summary
Analysts pointed to SEL-212’s more favorable dosing and adverse event profile with fewer limitations that may harm compliance versus Krystexxa from Horizon, which is soon to be acquired by Amgen.
You may also be interested in...
Deal Watch: Graphite Exits Via Reverse Merger With Presbyopia Specialist LENZ
Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.
Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.
Amgen’s $27.8bn Horizon Takeover Stipulates Biosimilar Restrictions
The FTC’s proposed consent order allowing Amgen to move ahead with its mammoth takeover of Horizon includes an interesting stipulation for industry – one involving biosimilars.